$2.29 EPS Expected for Chubb Limited (CB); NovoCure Limited (NVCR) Had 3 Analysts Last Week

January 18, 2018 - By Kurt Siggers

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. As per Wednesday, December 2, the company rating was initiated by Deutsche Bank. On Tuesday, October 27 the stock rating was initiated by Wedbush with “Outperform”. The company was initiated on Tuesday, October 27 by JMP Securities. The firm earned “Overweight” rating on Tuesday, October 27 by JP Morgan. Barclays Capital initiated it with “Underweight” rating and $16 target in Tuesday, January 19 report. On Friday, July 29 the stock rating was maintained by Wedbush with “Outperform”. See NovoCure Limited (NASDAQ:NVCR) latest ratings:

Analysts expect Chubb Limited (NYSE:CB) to report $2.29 EPS on January, 30.They anticipate $0.43 EPS change or 15.81% from last quarter’s $2.72 EPS. CB’s profit would be $1.06 billion giving it 16.11 P/E if the $2.29 EPS is correct. After having $-0.13 EPS previously, Chubb Limited’s analysts see -1,861.54% EPS growth. The stock increased 1.28% or $1.87 during the last trading session, reaching $147.54. About 1.73 million shares traded or 16.19% up from the average. Chubb Limited (NYSE:CB) has risen 10.92% since January 18, 2017 and is uptrending. It has underperformed by 5.78% the S&P500.

The stock decreased 2.12% or $0.45 during the last trading session, reaching $20.75. About 1.08M shares traded or 17.76% up from the average. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since January 18, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $1.85 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

Among 22 analysts covering The Chubb Corporation (NYSE:CB), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. The Chubb Corporation had 47 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Tuesday, November 22. The firm has “Buy” rating given on Wednesday, July 5 by Keefe Bruyette & Woods. RBC Capital Markets maintained the shares of CB in report on Monday, July 10 with “Buy” rating. Keefe Bruyette & Woods maintained Chubb Limited (NYSE:CB) rating on Friday, October 27. Keefe Bruyette & Woods has “Buy” rating and $153.0 target. Tudor Pickering upgraded the shares of CB in report on Wednesday, October 28 to “Buy” rating. As per Friday, July 24, the company rating was upgraded by Janney Capital. The firm has “Market Perform” rating by BMO Capital Markets given on Monday, July 11. The firm has “Outperform” rating by Bernstein given on Friday, July 31. Wood maintained the shares of CB in report on Friday, April 28 with “Buy” rating. On Thursday, April 27 the stock rating was maintained by RBC Capital Markets with “Outperform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: